507 related articles for article (PubMed ID: 30872517)
1. Ushering in the next generation of precision trials for pediatric cancer.
DuBois SG; Corson LB; Stegmaier K; Janeway KA
Science; 2019 Mar; 363(6432):1175-1181. PubMed ID: 30872517
[TBL] [Abstract][Full Text] [Related]
2. Precision medicine in pediatric oncology.
Forrest SJ; Geoerger B; Janeway KA
Curr Opin Pediatr; 2018 Feb; 30(1):17-24. PubMed ID: 29189430
[TBL] [Abstract][Full Text] [Related]
3. Pediatric oncology enters an era of precision medicine.
Seibel NL; Janeway K; Allen CE; Chi SN; Cho YJ; Glade Bender JL; Kim A; Laetsch TW; Irwin MS; Takebe N; Tricoli JV; Parsons DW
Curr Probl Cancer; 2017; 41(3):194-200. PubMed ID: 28343740
[TBL] [Abstract][Full Text] [Related]
4. Precision Medicine in Pediatric Oncology.
Vo KT; Parsons DW; Seibel NL
Surg Oncol Clin N Am; 2020 Jan; 29(1):63-72. PubMed ID: 31757314
[TBL] [Abstract][Full Text] [Related]
5. From Tissue-Agnostic to N-of-One Therapies: (R)Evolution of the Precision Paradigm.
Adashek JJ; Subbiah V; Kurzrock R
Trends Cancer; 2021 Jan; 7(1):15-28. PubMed ID: 33008795
[TBL] [Abstract][Full Text] [Related]
6. Precision oncology: A new era of cancer clinical trials.
Renfro LA; An MW; Mandrekar SJ
Cancer Lett; 2017 Feb; 387():121-126. PubMed ID: 26987624
[TBL] [Abstract][Full Text] [Related]
7. Impact of the biomarker enrichment strategy in drug development.
Lara Gongora AB; Carvalho Oliveira LJ; Jardim DL
Expert Rev Mol Diagn; 2020 Jun; 20(6):611-618. PubMed ID: 31903795
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine for pediatric cancers lags behind that for adult cancers: Citing hurdles in clinical trial recruitment and drug development, researchers are exploring ways to close gaps.
Printz C
Cancer; 2020 Jan; 126(2):239-240. PubMed ID: 31917472
[No Abstract] [Full Text] [Related]
9. Advancing cancer drug development through precision medicine and innovative designs.
Zhang W; Wang J; Menon S
J Biopharm Stat; 2018; 28(2):229-244. PubMed ID: 29173004
[TBL] [Abstract][Full Text] [Related]
10. New approaches to therapeutic drug development for childhood cancers.
Campbell K; Ma C; DuBois SG
Curr Opin Pediatr; 2020 Feb; 32(1):35-40. PubMed ID: 31790026
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Sequencing in Oncology in the Era of Precision Medicine.
Blumenthal GM; Mansfield E; Pazdur R
JAMA Oncol; 2016 Jan; 2(1):13-4. PubMed ID: 26540172
[No Abstract] [Full Text] [Related]
12. Clinical trials in the era of personalized oncology.
Maitland ML; Schilsky RL
CA Cancer J Clin; 2011; 61(6):365-81. PubMed ID: 22034206
[TBL] [Abstract][Full Text] [Related]
13. Personalized Medicine: Genomics Trials in Oncology.
Hayes DF; Schott AF
Trans Am Clin Climatol Assoc; 2015; 126():133-43. PubMed ID: 26330667
[TBL] [Abstract][Full Text] [Related]
14. Evolving paradigms for new agent development in pediatric oncology.
Flynn A; Fox E
Curr Opin Pediatr; 2018 Feb; 30(1):10-16. PubMed ID: 29176356
[TBL] [Abstract][Full Text] [Related]
15. Basket Studies: Redefining Clinical Trials in the Era of Genome-Driven Oncology.
Tao JJ; Schram AM; Hyman DM
Annu Rev Med; 2018 Jan; 69():319-331. PubMed ID: 29120700
[TBL] [Abstract][Full Text] [Related]
16. Molecular Tumor Boards in Clinical Practice.
Luchini C; Lawlor RT; Milella M; Scarpa A
Trends Cancer; 2020 Sep; 6(9):738-744. PubMed ID: 32517959
[TBL] [Abstract][Full Text] [Related]
17. Implementing precision cancer medicine in the genomic era.
Chen HZ; Bonneville R; Roychowdhury S
Semin Cancer Biol; 2019 Apr; 55():16-27. PubMed ID: 29857039
[TBL] [Abstract][Full Text] [Related]
18. Definitions and statistical properties of master protocols for personalized medicine in oncology.
Renfro LA; Mandrekar SJ
J Biopharm Stat; 2018; 28(2):217-228. PubMed ID: 28877008
[TBL] [Abstract][Full Text] [Related]
19. Toward a More Precise Future for Oncology.
Murciano-Goroff YR; Taylor BS; Hyman DM; Schram AM
Cancer Cell; 2020 Apr; 37(4):431-442. PubMed ID: 32289268
[TBL] [Abstract][Full Text] [Related]
20. Novel Therapeutic Interventions Early in the Disease Trajectory: Drug Development Beyond the Refractory Setting.
Hafez N; Rugo HS; Tempero MA; Fox E; Reaman GH; Lyerly HK; Walker D; LoRusso PM
Clin Cancer Res; 2020 Sep; 26(18):4743-4747. PubMed ID: 32571790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
